Actively Recruiting
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Led by Benjamin T Diamond, MD · Updated on 2026-03-11
30
Participants Needed
1
Research Sites
366 weeks
Total Duration
On this page
Sponsors
B
Benjamin T Diamond, MD
Lead Sponsor
B
Bristol-Myers Squibb
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.
CONDITIONS
Official Title
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of multiple myeloma with progressive disease within 60 days of last treatment
- Received 1 to 3 prior therapies including lenalidomide
- Measurable disease defined by specific protein levels or free light chain abnormalities
- Prior CD38 or carfilzomib therapy allowed if certain response and tolerance criteria met
- Creatinine clearance of 60 ml/min or higher
- Age between 18 and 75 years
- ECOG performance status of 0 to 2
- Adequate blood counts unless cytopenias due to disease
- Liver function tests within specified limits
- Ability to tolerate thromboprophylaxis (blood clot prevention)
- Negative pregnancy test and use of effective birth control for females of childbearing potential
- Agreement to use contraception for men and females as specified
You will not qualify if you...
- Receiving other systemic treatments for multiple myeloma except certain supportive care
- Refractory to anti-CD38 therapy
- Diagnosis of plasma cell leukemia
- Having POEMS syndrome or amyloidosis
- Severe chronic obstructive pulmonary disease (FEV1 < 50%)
- Pregnant or breastfeeding
- Uncontrolled hypertension or diabetes
- Active hepatitis B or C infection without sustained viral response
- Positive for HIV or active hepatitis B or C without proper control
- Significant heart disease or recent heart attack
- Pulmonary hypertension
- Severe gastrointestinal disease preventing oral medication absorption
- Uncontrolled infections or psychiatric conditions affecting compliance
- Severe neuropathy (Grade 3 or higher with pain)
- Contraindications to study medications
- Major surgery within 3 weeks prior to starting treatment
- Prior treatment with iberdomide
- Plans for pregnancy or sperm/egg donation during and after treatment
- Limited decision-making capacity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Miami
Miami, Florida, United States, 33136
Actively Recruiting
Research Team
M
Michelle D Armogan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here